We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.25 | -35.71% | 2.25 | 2.00 | 2.50 | 2.25 | 1.75 | 1.875 | 28,795,760 | 16:29:45 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -0.50 | 2.59M |
From May 2019 to May 2024
TIDMGDR
RNS Number : 5633L
Genedrive PLC
09 September 2019
genedrive plc
("genedrive" or the "Company")
Notice of Results
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its preliminary results for the year ended 30 June 2019 on Thursday, 3 October 2019.
For further details please contact:
Hot Features
Premium
genedrive plc www.genedriveplc.com
David Budd: CEO / Matthew Fowler: CFO +44 (0)161 989 0245
Peel Hunt LLP +44 (0)20 7418 8900
James Steel / Oliver Jackson
Stanford Capital Partners Limited +44 (0)20 3815 8880
Patrick Claridge / John Howes
Walbrook PR Ltd (Media Relations +44 (0)20 7933 8780 or genedrive@walbrookpr.com
& Investor Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) HCV-ID kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive(R) platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive(R) HCV-ID Kit and Genedrive(R) platform in India. The Company has assays on market for the detection of certain biological targets and has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).
Further details can be found at: www.genedriveplc.com and www.genedrive.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORLFMATMBMMBBL
(END) Dow Jones Newswires
September 09, 2019 02:01 ET (06:01 GMT)
1 Year Genedrive Chart |
1 Month Genedrive Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
